EU News
Printable version

Coronavirus: Commission offers financing to innovative vaccines company CureVac

The Commission yesterday offered up to €80 million of financial support to CureVac, a higly innovative vaccine developer from Tübingen, Germany, to scale up development and production of a vaccine against the Coronavirus in Europe. Commission President Ursula von der Leyen and Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, discussed with the CureVac management via videoconference. The Vice-President of the European Investment Bank (EIB), Ambroise Fayolle, also participated. The support would come in form of an EU guarantee of a currently assessed EIB loan of an identical amount, in the framework of the InnovFin Infectious Disease Finance Facility under Horizon 2020.

Commission President Ursula von der Leyen yesterday said: 

“In this public health crisis it is of utmost importance that we support our leading researchers and tech companies. We are determined to provide CureVac with the financing it needs to quickly scale up development and production of a vaccine against the Coronavirus. I am proud that we have leading companies like CureVac in the EU. Their home is here. But their vaccines will benefit everyone, in Europe and beyond.”

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, yesterday said: 

“Supporting excellent EU research and innovation is an essential part of our coordinated response against the spread of the Coronavirus. In 2014, CureVac won EU's first ever innovation inducement prize. We are committed to support further its EU-based research and innovation in these critical times. Science and innovation in Europe are at the heart of our policies for protecting people's health.”

Ambroise Fayolle, Vice-President for Innovation in the European Investment Bank, yesterday said: 

“The EIB is and remains the EU Bank for innovation, even more than ever in the current health crisis. Thanks to our strong and fruitful long partnership with the Commission in the area of research and innovation financial instruments (InnovFin), we are determined to do our best to support CureVac scale up needs for the benefits of EU citizen and beyond.”   

Founded in 2000, CureVac is a German biopharmaceutical company that has developed a novel technology to overcome one of the biggest barriers to using vaccines: the need to keep them stable without refrigeration. Its vaccine technology is based on messenger RNA (mRNA) molecules that stimulate the immune system. Preliminary studies have shown that the technology holds a promise for rapid response to COVID-19. If proven, millions of vaccine doses could potentially be produced at low costs in existing CureVac production facilities. CureVac has already started its COVID-19 vaccine development program and estimates to launch clinical testing by June 2020.

The Commission recognised CureVac's potential to bring life-saving vaccines to people across the planet in safe and affordable ways already in 2014 when CureVac received the first ever EU innovation inducement prize of €2 million, funded by the EU's research and innovation programme, FP7. The award was intended to support further development of the breakthrough idea. Now the Commission and the EIB are strengthening jointly their efforts to provide the necessary means to CureVac, taking advantage of their long and fruitful cooperation in financial instruments dedicated to support research and innovation such as Horizon 2020 InnovFin and in particular its Infectious Disease Finance Facility.

Click here for the full press release

 

Original article link: https://ec.europa.eu/commission/presscorner/detail/en/IP_20_474

Share this article

Latest News from
EU News

A GUIDE TO CONTINUITY PLANNING IN THE PUBLIC SECTOR